- Home
- JPC vs IBRX Comparison
JPC vs IBRX Comparison
Compare JPC & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPC
- IBRX
- Stock Information
- Founded
- JPC 2003
- IBRX 2014
- Country
- JPC United States
- IBRX United States
- Employees
- JPC N/A
- IBRX N/A
- Industry
- JPC Investment Managers
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JPC Finance
- IBRX Health Care
- Exchange
- JPC Nasdaq
- IBRX Nasdaq
- Market Cap
- JPC 2.5B
- IBRX 2.3B
- IPO Year
- JPC N/A
- IBRX N/A
- Fundamental
- Price
- JPC $8.08
- IBRX $2.31
- Analyst Decision
- JPC
- IBRX Strong Buy
- Analyst Count
- JPC 0
- IBRX 5
- Target Price
- JPC N/A
- IBRX $10.20
- AVG Volume (30 Days)
- JPC 998.5K
- IBRX 8.9M
- Earning Date
- JPC 01-01-0001
- IBRX 08-05-2025
- Dividend Yield
- JPC 7.57%
- IBRX N/A
- EPS Growth
- JPC N/A
- IBRX N/A
- EPS
- JPC N/A
- IBRX N/A
- Revenue
- JPC N/A
- IBRX $56,600,000.00
- Revenue This Year
- JPC N/A
- IBRX $567.98
- Revenue Next Year
- JPC N/A
- IBRX $160.56
- P/E Ratio
- JPC N/A
- IBRX N/A
- Revenue Growth
- JPC N/A
- IBRX 4227.22
- 52 Week Low
- JPC $5.94
- IBRX $1.83
- 52 Week High
- JPC $7.36
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- JPC 53.83
- IBRX 40.64
- Support Level
- JPC $8.05
- IBRX $2.17
- Resistance Level
- JPC $8.13
- IBRX $2.94
- Average True Range (ATR)
- JPC 0.04
- IBRX 0.15
- MACD
- JPC -0.00
- IBRX -0.02
- Stochastic Oscillator
- JPC 45.00
- IBRX 18.18
About JPC Nuveen Preferred & Income Opportunities Fund
Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. It invests its managed assets in preferred securities, and in other types of securities, primarily income-oriented securities such as corporate and taxable municipal debt and common equity.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.